- Home
- ACLX vs CRSP Comparison
ACLX vs CRSP Comparison
Compare ACLX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- CRSP
- Stock Information
- Founded
- ACLX 2015
- CRSP 2013
- Country
- ACLX United States
- CRSP Switzerland
- Employees
- ACLX N/A
- CRSP N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACLX Health Care
- CRSP Health Care
- Exchange
- ACLX Nasdaq
- CRSP Nasdaq
- Market Cap
- ACLX 4.1B
- CRSP 4.9B
- IPO Year
- ACLX 2022
- CRSP 2016
- Fundamental
- Price
- ACLX $78.00
- CRSP $55.87
- Analyst Decision
- ACLX Strong Buy
- CRSP Buy
- Analyst Count
- ACLX 13
- CRSP 16
- Target Price
- ACLX $114.75
- CRSP $72.27
- AVG Volume (30 Days)
- ACLX 538.2K
- CRSP 2.0M
- Earning Date
- ACLX 11-06-2025
- CRSP 11-04-2025
- Dividend Yield
- ACLX N/A
- CRSP N/A
- EPS Growth
- ACLX N/A
- CRSP N/A
- EPS
- ACLX N/A
- CRSP N/A
- Revenue
- ACLX $56,979,000.00
- CRSP $38,050,000.00
- Revenue This Year
- ACLX N/A
- CRSP $11.17
- Revenue Next Year
- ACLX $174.18
- CRSP $296.09
- P/E Ratio
- ACLX N/A
- CRSP N/A
- Revenue Growth
- ACLX N/A
- CRSP N/A
- 52 Week Low
- ACLX $47.86
- CRSP $30.04
- 52 Week High
- ACLX $107.37
- CRSP $71.13
- Technical
- Relative Strength Index (RSI)
- ACLX 70.10
- CRSP 53.85
- Support Level
- ACLX $70.11
- CRSP $51.63
- Resistance Level
- ACLX $73.10
- CRSP $55.59
- Average True Range (ATR)
- ACLX 2.51
- CRSP 2.04
- MACD
- ACLX 0.69
- CRSP 0.25
- Stochastic Oscillator
- ACLX 97.42
- CRSP 96.87
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.